Drug Trial Radar · NCT01221623
Study of AA4500 in the Treatment of Peyronie's Disease
Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
418
Actual
Start
Oct 2010
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 300 (200 AA4500 and 100 placebo) men will be randomized. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle. Before dosing, subjects will be stratified by degree of penile curvature (ie, 30º to 60º or 61º to 90º) and then randomized into two treatment groups to receive in a 2:1 ratio either AA4500 0.58 mg or placebo. In this study, qualified subjects may receive up to four treatment cycles; each cycle will be separated by a period of 42 days (± 5 days). During each treatment cycle, subjects will receive two injections of study drug with at least 24 hours but not more than 72 hours between injections. After the final injection of each treatment cycle, the investigator or qualified designee will model the penile plaque in an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to \< 15 degrees after the first, second, or third cycle of injections or if the investigator determines further treatment is not clinically indicated (eg, adverse events; allergic reaction), subsequent treatment cycles will not be administered. Following the maximum of four treatment cycles, each subject will be followed for additional safety and efficacy assessments on Days 169 (± 7 days), 232 (± 7 days), 295 (± 7 days), 365 (± 7 days) (nominal weeks 24, 33, 42 and 52). Subjects randomized to placebo may receive open-label AA4500 treatment after completing this study as part of another protocol.
Conditions
- Peyronie's Disease
Interventions
AA4500Biological
2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
PlaceboBiological
2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change From Baseline in Penile CurvatureTime frame: Baseline and Week 52
- Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)Time frame: Baseline and Week 52
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
Costal Clinical Research, Inc.
Mobile, Alabama
Alaska Clinical Research Center, LLC
Anchorage, Alaska
Connect Clinical Research Center (CCRC)
Phoenix, Arizona
So. Orange County Medical Research Center
Laguna Hills, California
The Urology Center of Colorado
Denver, Colorado
Connecticut Clinical Resarch Center, LLC
Middlebury, Connecticut
South Florida Medical Research
Aventura, Florida
Winter Park Urology Associates
Orlando, Florida
Idaho Urologic Institute
Meridian, Idaho
Northeast Indiana Research, LLC
Fort Wayne, Indiana
Metropolitan Urology, P.S.C.
Jeffersonville, Indiana
Kansas City Urology Care, P.A. Research Department
Overland Park, Kansas
Tulane University Health Sciences Center Dept. of Urology
New Orleans, Louisiana
Regional Urology L.L.C.
Shreveport, Louisiana
Chesapeake Urology Research Assoc.
Glen Burnie, Maryland
Chesapeake Urology Research Assoc., PA
Towson, Maryland
University of Michigan
Ann Arbor, Michigan
Cooper Health System
Camden, New Jersey
AdvanceMed Research
Lawrenceville, New Jersey
The Capital Region Medical Research Foundation @ the Urological Institute of Northeastern New York
Albany, New York
Bruce R. Gilbert, MD, PhD, PC
Great Neck, New York
University Urology Associates
New York, New York
Michael A. Werner, MD, PC
Purchase, New York
Universitiy of North Carolina School of Medicine Div. of Urology
Chapel Hill, North Carolina
Duke University Medical Center Division of Urologic Surgery
Durham, North Carolina
The Miriam Hospital
Providence, Rhode Island
Research Across America
Carrollton, Texas
Urology Clinics of North Texas, PA
Dallas, Texas
Urology San Antonio Research, PA
San Antonio, Texas
Urology Sydney
Kogarah, New South Wales, Australia
Health Pac Medical Centre
Sydney, New South Wales, Australia
AusTrials Pty Limited
Brisbane, Queensland, Australia
Bayside Urology
Mentone, Victoria, Australia
Keogh Institute for Medical Research
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.